Cancers (Jul 2023)
Trends in Cancer Incidence in Different Antiretroviral Treatment-Eras amongst People with HIV
- Lauren Greenberg,
- Lene Ryom,
- Elzbieta Bakowska,
- Ferdinand Wit,
- Heiner C. Bucher,
- Dominique L. Braun,
- Andrew Phillips,
- Caroline Sabin,
- Antonella d’Arminio Monforte,
- Robert Zangerle,
- Colette Smith,
- Stéphane De Wit,
- Fabrice Bonnet,
- Christian Pradier,
- Cristina Mussini,
- Camilla Muccini,
- Jörg J. Vehreschild,
- Jennifer Hoy,
- Veronica Svedhem,
- Jose M. Miró,
- Jan-Christian Wasmuth,
- Peter Reiss,
- Josep M. Llibre,
- Nikoloz Chkhartishvili,
- Christoph Stephan,
- Camilla I. Hatleberg,
- Bastian Neesgaard,
- Lars Peters,
- Nadine Jaschinski,
- Nikos Dedes,
- Elena Kuzovatova,
- Marc Van Der Valk,
- Marianna Menozzi,
- Clara Lehmann,
- Kathy Petoumenos,
- Harmony Garges,
- Jim Rooney,
- Lital Young,
- Jens D. Lundgren,
- Loveleen Bansi-Matharu,
- Amanda Mocroft,
- on behalf of the RESPOND and D:A:D Study Groups
Affiliations
- Lauren Greenberg
- CHIP, Centre of Excellence for Health, Immunity and Infections Rigshospitalet, University of Copenhagen, DK-2100 Copenhagen, Denmark
- Lene Ryom
- CHIP, Centre of Excellence for Health, Immunity and Infections Rigshospitalet, University of Copenhagen, DK-2100 Copenhagen, Denmark
- Elzbieta Bakowska
- Wojewódzki Szpital Zakaźny, 01-201 Warsaw, Poland
- Ferdinand Wit
- Stichting HIV Monitoring, 1105 BD Amsterdam, The Netherlands
- Heiner C. Bucher
- Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, 8001 Zurich, Switzerland
- Dominique L. Braun
- Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, 8001 Zurich, Switzerland
- Andrew Phillips
- Centre for Clinical Research, Epidemiology, Modelling and Evaluation, Institute for Global Health, University College London, London NW3 2PF, UK
- Caroline Sabin
- Centre for Clinical Research, Epidemiology, Modelling and Evaluation, Institute for Global Health, University College London, London NW3 2PF, UK
- Antonella d’Arminio Monforte
- Italian Cohort Naive Antiretrovirals (ICONA), ASST Santi Paolo e Carlo, 20142 Milano, Italy
- Robert Zangerle
- Austrian HIV Cohort Study (AHIVCOS), Medizinische Universität Innsbruck, 6020 Innsbruch, Austria
- Colette Smith
- The Royal Free HIV Cohort Study, Royal Free Hospital, University College London, London NW3 2PF, UK
- Stéphane De Wit
- CHU Saint-Pierre, Centre de Recherche en Maladies Infectieuses a.s.b.l., 1000 Brussels, Belgium
- Fabrice Bonnet
- CHU de Bordeaux and Bordeaux University, BPH, INSERM U1219, 33076 Bordeaux, France
- Christian Pradier
- Nice HIV Cohort, Université Côte d’Azur et Centre Hospitalier Universitaire, 06000 Nice, France
- Cristina Mussini
- Modena HIV Cohort, Università Degli Studi Di Modena and Reggio Emilia, 41125 Modena, Italy
- Camilla Muccini
- San Raffaele Scientific Institute, Università Vita-Salute San Raffaele, 20132 Milano, Italy
- Jörg J. Vehreschild
- University Hospital Cologne, 50937 Cologne, Germany
- Jennifer Hoy
- Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne 3004, Australia
- Veronica Svedhem
- Swedish InfCareHIV Cohort, Karolinska University Hospital, 141 86 Stockholm, Sweden
- Jose M. Miró
- Infectious Diseases Service, Hospital Clinic-IDIBAPS, University of Barcelona, 08036 Barcelona, Spain
- Jan-Christian Wasmuth
- University Hospital Bonn, 53127 Bonn, Germany
- Peter Reiss
- Amsterdam UMC Location, Department of Global Health, University of Amsterdam, Global Health, Meibergdreef 9, 1105 Amsterdam, The Netherlands
- Josep M. Llibre
- Department of Infectious Diseases, Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Spain
- Nikoloz Chkhartishvili
- Georgian National AIDS Health Information System (AIDS HIS), Infectious Diseases, AIDS and Clinical Immunology Research Center, Tbilisi, Georgia
- Christoph Stephan
- HIV Center, University Hospital Frankfurt, Goethe-University, 60596 Frankfurt, Germany
- Camilla I. Hatleberg
- CHIP, Centre of Excellence for Health, Immunity and Infections Rigshospitalet, University of Copenhagen, DK-2100 Copenhagen, Denmark
- Bastian Neesgaard
- CHIP, Centre of Excellence for Health, Immunity and Infections Rigshospitalet, University of Copenhagen, DK-2100 Copenhagen, Denmark
- Lars Peters
- CHIP, Centre of Excellence for Health, Immunity and Infections Rigshospitalet, University of Copenhagen, DK-2100 Copenhagen, Denmark
- Nadine Jaschinski
- CHIP, Centre of Excellence for Health, Immunity and Infections Rigshospitalet, University of Copenhagen, DK-2100 Copenhagen, Denmark
- Nikos Dedes
- European AIDS Treatment Group, 1000 Brussels, Belgium
- Elena Kuzovatova
- Nizhny Novgorod Scientific and Research Institute, 603155 Nizhny Novgorod, Russia
- Marc Van Der Valk
- Stichting HIV Monitoring, 1105 BD Amsterdam, The Netherlands
- Marianna Menozzi
- Modena HIV Cohort, Università Degli Studi Di Modena and Reggio Emilia, 41125 Modena, Italy
- Clara Lehmann
- University Hospital Cologne, 50937 Cologne, Germany
- Kathy Petoumenos
- Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne 3004, Australia
- Harmony Garges
- ViiV Healthcare, Research Triangle Park, Durham, NC 27709, USA
- Jim Rooney
- Gilead Science, Foster City, CA 94404, USA
- Lital Young
- Merck Sharp & Dohme, Rahway, NJ 07065, USA
- Jens D. Lundgren
- CHIP, Centre of Excellence for Health, Immunity and Infections Rigshospitalet, University of Copenhagen, DK-2100 Copenhagen, Denmark
- Loveleen Bansi-Matharu
- Centre for Clinical Research, Epidemiology, Modelling and Evaluation, Institute for Global Health, University College London, London NW3 2PF, UK
- Amanda Mocroft
- CHIP, Centre of Excellence for Health, Immunity and Infections Rigshospitalet, University of Copenhagen, DK-2100 Copenhagen, Denmark
- on behalf of the RESPOND and D:A:D Study Groups
- DOI
- https://doi.org/10.3390/cancers15143640
- Journal volume & issue
-
Vol. 15,
no. 14
p. 3640
Abstract
Despite cancer being a leading comorbidity amongst individuals with HIV, there are limited data assessing cancer trends across different antiretroviral therapy (ART)-eras. We calculated age-standardised cancer incidence rates (IRs) from 2006–2021 in two international cohort collaborations (D:A:D and RESPOND). Poisson regression was used to assess temporal trends, adjusted for potential confounders. Amongst 64,937 individuals (31% ART-naïve at baseline) and 490,376 total person-years of follow-up (PYFU), there were 3763 incident cancers (IR 7.7/1000 PYFU [95% CI 7.4, 7.9]): 950 AIDS-defining cancers (ADCs), 2813 non-ADCs, 1677 infection-related cancers, 1372 smoking-related cancers, and 719 BMI-related cancers (groups were not mutually exclusive). Age-standardised IRs for overall cancer remained fairly constant over time (8.22/1000 PYFU [7.52, 8.97] in 2006–2007, 7.54 [6.59, 8.59] in 2020–2021). The incidence of ADCs (3.23 [2.79, 3.72], 0.99 [0.67, 1.42]) and infection-related cancers (4.83 [4.2, 5.41], 2.43 [1.90, 3.05]) decreased over time, whilst the incidence of non-ADCs (4.99 [4.44, 5.58], 6.55 [5.67, 7.53]), smoking-related cancers (2.38 [2.01, 2.79], 3.25 [2.63–3.96]), and BMI-related cancers (1.07 [0.83, 1.37], 1.88 [1.42, 2.44]) increased. Trends were similar after adjusting for demographics, comorbidities, HIV-related factors, and ART use. These results highlight the need for better prevention strategies to reduce the incidence of NADCs, smoking-, and BMI-related cancers.
Keywords
